Medpace Holdings Inc vs Wayfair Inc — how do they compare? Medpace Holdings Inc trades at $597.39 (market cap $16.90B), while Wayfair Inc trades at $102.74 (market cap $14.14B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Wayfair Inc nearer its low. Which is the better fit depends on your goals.
| MEDP | W | |
|---|---|---|
Market Cap | $16.90B | $14.14B |
Sector | Technology | Consumer Cyclical |
52-Week High | $620.59 | $119.05 |
52-Week Low | $393.42 | $57.40 |
Enterprise Value | $16.52B | $16.47B |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Wayfair (W) trades at $102.79, down 0.52% on the day, with a bullish technical signal supported by a golden cross and recent 30% post-earnings rally. Q2 2026 EPS of $0.95 beat estimates, driven by 7.5% revenue growth and strong U.S. demand, though net margins remain negative. Analyst consensus is bullish with a $122 price target, citing market share gains and margin expansion prospects.
Outlook: Growth momentum and positive sentiment offer upside potential, but risks include persistent losses, high debt-to-asset ratio (95.11% in 2025), and volatile consumer spending. Investors should weigh robust U.S. performance against international weakness and profitability challenges.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →